EPOCH 20: BIOTECH MARKET RESEARCH $SANA

Sana Biotechnology

Mark your calendars - Sana Biotechnology is expected to share human data on initial cell persistence from HIP approaches in T1D. Why is this interesting to us?  Because allogeneic cell therapies have a massive unanswered question - durability.  Those of us that follow the space are aware of the immune silencing edits which have been implemented by Sana and their competitors.  They all make sense and look great on a ppt slide.  But will they work?  This data release will lend clarity to that question.  Options pricing suggest 90% volatility!  

Be sure to read through to the end for a special update on how much biotech stocks move on approval announcements.

Every Monday we are out with public biotech research, profiling biotech companies with near term catalysts. This will focus primarily on the major market moving biotech events such as data readouts from the major scientific conferences as well as potential regulatory approvals.

We will not offer specific trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely materially drive stock prices (sometimes +/-100% in either direction).

Be sure to SUBSCRIBE to not miss.

HOW TO PLAY BIOTECH APPROVAL/DATA READOUTS ANNOUNCEMENTS

While biotech equities will move on news of announcement, often if there is high conviction in a positive read, a large run up ahead of the news will occur and the actual event turns into a sell the news event. Sometimes, investors wait for the actual event to make a long/short decision. And obviously if the news is disappointing (more often than not) the stock will tank.

This is not financial advice so you will have to make your own call on how to best play these events. Our aim is simply to flag catalysts with high projected volatility.

ALERT: Phase I data from UP-421 T1D hypoimmune data from primary islet cells

DATE: Q2 2024

IMPLIED VOLATILITY: +/- 90%

BACKGROUND: